Article
Oncology
H. S. Han, B. K. Arun, B. Kaufman, H. Wildiers, M. Friedlander, J. P. Ayoub, S. L. Puhalla, B. A. Bach, M. G. Kundu, N. Khandelwal, D. Feng, S. Bhattacharya, D. Maag, C. K. Ratajczak, V Dieras
Summary: Adding the poly(ADP-ribose) polymerase inhibitor veliparib to carboplatin/paclitaxel treatment can improve progression-free survival in advanced breast cancer patients, and maintenance monotherapy with veliparib has a tolerable safety profile.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Lauren Averett Byers, Dmitry Bentsion, Steven Gans, Konstantin Penkov, ChoonHee Son, Anne Sibille, Taofeek K. Owonikoko, Harry J. M. Groen, Carl M. Gay, Junya Fujimoto, Patricia de Groot, Martin Dunbar, Kingston Kang, Lei He, Vasudha Sehgal, Jaimee Glasgow, Bruce Allen Bach, Peter M. Ellis
Summary: The study found that veliparib combined with platinum chemotherapy and maintenance therapy improved progression-free survival in first-line treatment of ED-SCLC, but did not show a corresponding benefit in overall survival. Patients may experience common hematologic toxicities during treatment. Further research is needed to determine the role of biomarkers in this setting.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Ramaswamy Govindan, Mike Lind, Amelia Insa, Saad A. Khan, Dmitry Uskov, Ali Tafreshi, Salih Guclu, Jair Bar, Terufumi Kato, Ki Hyeong Lee, Kazuhiko Nakagawa, Olfred Hansen, Bonne Biesma, Madan G. Kundu, Martin Dunbar, Lei He, Peter Ansell, Vasudha Sehgal, Xin Huang, Jaimee Glasgow, Bruce A. Bach
Summary: Patients with advanced non-squamous non-small cell lung cancers without oncogenic drivers did not show survival benefits from veliparib plus chemotherapy. However, a trend towards improved survival was observed in a subgroup of patients. The LP52 gene signature may be useful in identifying patients who are more likely to benefit from veliparib.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Banu K. Arun, Hyo S. Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L. Puhalla, Katherine M. Bell-McGuinn, Bruce A. Bach, Madan G. Kundu, Christine K. Ratajczak, David Maag, Veronique Dieras
Summary: In patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer, the addition of veliparib to carboplatinepaclitaxel improves progression-free survival, especially in first-line patients without previous cytotoxic therapy for metastatic disease, suggesting significant efficacy of this treatment approach.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Michael J. Jelinek, Nathan R. Foster, Alex J. Zoroufy, Gary K. Schwartz, Pamela N. Munster, Tanguy Y. Seiwert, Jonas A. de Souza, Everett E. Vokes
Summary: This study evaluated the maximum tolerated dose and safety of veliparib combined with carboplatin and paclitaxel induction chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. A total of 20 patients were enrolled, with 18 patients analyzed. The addition of veliparib to chemotherapy was well tolerated, with hematologic toxicities being the most common adverse events.
Article
Medicine, General & Internal
Musa Baris Aykan, Gul Sema Yildiran, Ece Akcan, Ramazan Acar, Ismail Erturk, Nuri Karadurmus
Summary: The objective of this study was to determine the survival endpoints and treatment-related adverse events after the use of the GemPOx protocol in relapsed/refractory germ cell tumours (GCTs) who had previously received multi-line systemic treatments. The results showed that significant PFS and OS are achievable in patients with relapsed/refractory GCTs receiving multi-line systemic chemotherapy, with a manageable spectrum of haematological side effects observed with GemPOx.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2022)
Article
Oncology
Ismail Erturk, Nuri Karadurmus, Halil Kiziloz, Ramazan Acar, Birol Yildiz, Musa Baris Aykan, Ramazan Esen, Galip Buyukturan, Yuksel Urun, Gokhan Erdem, Fikret Arpaci
Summary: The study of 64 patients undergoing AHSCT for GCT demonstrated that using CE chemotherapy regimen can lead to high survival rates, with a median overall survival time of 21.5 months and a median progression-free survival time of 20 months, and a response rate of 72%.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2021)
Article
Oncology
Shannon L. Puhalla, Veronique Dieras, Banu K. Arun, Bella Kaufman, Hans Wildiers, Hyo S. Han, Jean-Pierre Ayoub, Vered Stearns, Yuan Yuan, Teresa Helsten, Bridget Riley-Gillis, Erin Murphy, Madan G. Kundu, Meijing Wu, David Maag, Christine K. Ratajczak, Cyril Y. Ramathal, Michael Friedlander
Summary: The crossover veliparib monotherapy showed limited antitumor activity in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer who experienced disease progression on placebo plus carboplatin/paclitaxel in the BROCADE3 trial. Additionally, it was found that veliparib activity was greater in patients with longer platinum-free intervals. Reversion mutations in BRCA may promote cross-resistance and limit veliparib activity after progression on platinum therapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Waisse Waissi, Jean-Christophe Ame, Carole Mura, Georges Noel, Helene Burckel
Summary: The combination of olaparib with gemcitabine-based chemoradiotherapy can significantly enhance radiosensitization in PDAC cell lines, leading to increased cell death and a more pronounced effect at high radiation doses.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Silvia Schmidtova, Natalia Udvorkova, Zuzana Cierna, Samuel Horak, Katarina Kalavska, Michal Chovanec, Lucia Rojikova, Miriam Vulevova, Lucia Kucerova, Michal Mego
Summary: The study found PARP expression in GCT cell lines and xenografts, but veliparib failed to increase the cytotoxicity of platinum-based drugs.
Review
Oncology
Jane Belfield, Charlotte Findlay-Line
Summary: This article provides a detailed description of the use of ultrasound in germ cell tumours and offers guidance on performing an ultrasound examination. It also includes the classification of germ cell tumours and describes the key features of different types of tumours. The challenges and pitfalls of ultrasound are discussed, as well as other applications of ultrasound in this patient group.
Article
Oncology
Suresh S. Ramalingam, Silvia Novello, Salih Zeki Guclu, Dmitry Bentsion, Zanete Zvirbule, Maria Szilasi, Reyes Bernabe, Konstantinos Syrigos, Lauren Averett Byers, Philip Clingan, Jair Bar, Everett E. Vokes, Ramaswamy Govindan, Martin Dunbar, Peter Ansell, Lei He, Xin Huang, Vasudha Sehgal, Jaimee Glasgow, Bruce A. Bach, Julien Mazieres
Summary: The study found no therapeutic benefit of adding veliparib to first-line chemotherapy in current smokers with advanced sqNSCLC. However, the LP52 signature may identify a subgroup of patients likely to derive benefit from veliparib with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice Chen, Jan H. Beumer, Janice M. Mehnert
Summary: The study aimed to evaluate the safety and efficacy of Veliparib in combination with cyclophosphamide and doxorubicin, showing that these combinations are safe and active in patients with metastatic breast cancer.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Review
Oncology
Aitziber Velado-Eguskiza, Laura Gomez-Santos, Iker Badiola, Francisco Jose Saez, Edurne Alonso
Summary: Despite the high survival rate of testicular germ cell tumors, the treatment's long-term side effects significantly impact patients' quality of life, highlighting the need for research on proprotein convertases as diagnostic biomarkers and therapeutic targets.
Review
Oncology
Omar Abughanimeh, Benjamin A. Teply
Summary: The management of refractory/relapsed GCTs is challenging, with treatments such as high-dose chemotherapy, conventional chemotherapy, and surgery being effective options. More research is needed to determine the optimal chemotherapy approach for refractory diseases. Immunotherapy is also being investigated as a potential treatment option in this setting.
CURRENT ONCOLOGY REPORTS
(2021)
Review
Oncology
Marek Makovnik, Katarina Rejlekova, Ivan Uhrin, Michal Mego, Michal Chovanec
Summary: Testicular germ cell tumors have unique biology and pathology, and proper radiographic assessment is crucial for clinical management. While advancements in imaging methods like MRI are suggested, more research is needed. PET scanning shows advantages in evaluating residual disease, particularly in seminoma patients, to avoid unnecessary surgeries.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Katarina Letkovska, Pavel Babal, Zuzana Cierna, Silvia Schmidtova, Veronika Liskova, Katarina Kalavska, Vera Miskovska, Samuel Horak, Katarina Rejlekova, Michal Chovanec, Jozef Mardiak, Pavel Janega, Michal Mego
Summary: GCTs exhibit lower expression of AIF compared to normal testicular tissue, which could promote cell survival and metastatic dissemination. The downregulation of AIF may serve as a potential therapeutic target in GCTs.
Article
Biochemistry & Molecular Biology
Katarina Kalavska, Zuzana Sestakova, Andrea Mlcakova, Katarina Kozics, Paulina Gronesova, Lenka Hurbanova, Viera Miskovska, Katarina Rejlekova, Daniela Svetlovska, Zuzana Sycova-Mila, Jana Obertova, Patrik Palacka, Jozef Mardiak, Michal Chovanec, Miroslav Chovanec, Michal Mego
Summary: This study delved into the intricate interactions between the immune tumor microenvironment (TME) and endogenous DNA damage levels in germ cell tumor (GCT) patients. The research revealed a significant increase in DNA damage levels in peripheral blood mononuclear cells (PBMCs) cocultivated with cisplatin-resistant GCT cell lines compared to sensitive counterparts. Moreover, higher endogenous DNA damage levels in GCT patients were independently associated with specific changes in immune cell populations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Meeting Abstract
Oncology
Michal Mego, Daniela Svetlovska, Maria Reckova, Katarina Kalavska, Jana Obertova, Patrik Palacka, Katarina Rejlekova, Valentina De Angelis, Zuzana Sycova-Mila, Michal Chovanec, Jozef Mardiak
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Michal Chovanec, Katarina Kalavska, Jana Obertova, Patrik Palacka, Katarina Rejlekova, Zuzana Sycova-Mila, Valentina De Angelis, Zuzana Orszaghova, Peter Lesko, Daniela Svetlovska, Beata Mladosievicova, Jozef Mardiak, Michal Pastorek, Barbora Vlkova, Peter Celec, Michal Mego
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Katarina Kalavska, Zuzana Sestakova, Andrea Mlcakova, Paulina Gronesova, Viera Miskovska, Katarina Rejlekova, Daniela Svetlovska, Zuzana Sycova-Mila, Jana Obertova, Patrik Palacka, Jozef Mardiak, Miroslav Chovanec, Michal Chovanec, Michal Mego
Summary: The study evaluated the role of different leukocyte subpopulations in testicular germ cell tumors (GCT) by analyzing 84 chemotherapy-naive GCT patients. Different innate/adaptive immune cell subpopulations were significantly associated with poor risk-related clinical features and survival outcomes. The findings contribute to a deeper understanding of the interactions between cancer and innate/adaptive immune response in GCT patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biology
Katarina Kalavska, Zuzana Sestakova, Andrea Mlcakova, Paulina Gronesova, Viera Miskovska, Katarina Rejlekova, Daniela Svetlovska, Zuzana Sycova-Mila, Jana Obertova, Patrik Palacka, Jozef Mardiak, Miroslav Chovanec, Michal Chovanec, Michal Mego
Summary: The SII level above the cut-off value of SII >= 1003 was associated with higher neutrophil percentages, while an inverse correlation was found with peripheral lymphocyte percentages. Additionally, the association between SII and lymphocyte subpopulations was driven by T-cell subpopulations. In innate immunity-cell subpopulations, a correlation was observed between SII level and neutrophils, as well as associations with eosinophil, basophil, natural killer cell, and dendritic cell percentages.
Article
Oncology
M. Mego, D. Svetlovska, V De Angelis, K. Kalavska, P. Lesko, M. Makovnik, J. Obertova, Z. Orszaghova, P. Palacka, M. Reckova, K. Rejlekova, Z. Sycova-Mila, J. Mardiak, M. Chovanec
Summary: This study investigated the efficacy and toxicity of ALDH inhibitor disulfiram in combination with cisplatin in patients with multiple relapsed/refractory GCTs. The results showed limited efficacy of disulfiram in restoring sensitivity to cisplatin in multiple relapsed/refractory GCTs.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Nikola Hapakova, Michal Chovanec, Katarina Rejlekova, Katarina Kalavska, Jana Obertova, Patrik Palacka, Valentina De Angelis, Daniela Svetlovska, Zuzana Sycova-Mila, Jozef Mardiak, Michal Mego
Summary: This study aimed to evaluate the effect of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis on the incidence of febrile neutropenia (FN) in patients with testicular germ cell tumors (GCTs) receiving chemotherapy. The results showed that primary G-CSF prophylaxis significantly reduced the incidence of FN in patients treated with first-line chemotherapy for GCTs, suggesting that it should be considered as a preventive measure for these patients.
Article
Oncology
Katarina Rejlekova, Katarina Kalavska, Marek Makovnik, Nikola Hapakova, Michal Chovanec, Valentina De Angelis, Jana Obertova, Patrik Palacka, Zuzana Sycova-Mila, Jozef Mardiak, Michal Mego
Summary: This retrospective study aimed to identify the risk factors associated with the development of choriocarcinoma syndrome (CS) in high-risk germ cell tumor (GCT) patients. The results showed that ECOG PS ≥ 2 and metastatic lung involvement ≥ 50% were independently associated with CS development.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Patrik Palacka, Jarmila Kucharska, Jana Obertova, Katarina Rejlekova, Jan Slopovsky, Michal Mego, Daniela Svetlovska, Boris Kollarik, Jozef Mardiak, Anna Gvozdjakova
Summary: Oxidative stress plays a significant role in cancer pathogenesis, and the level of thiobarbituric acid-reactive substances (TBARS)-a parameter of lipid peroxidation-has prognostic significance in chemotherapy-naive patients with metastatic urothelial carcinoma (mUC). The effect of cisplatin-based chemotherapy on oxidative stress, coenzyme Q(10), and antioxidants is still unknown.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Meeting Abstract
Oncology
Michal Mego, Daniela Svetlovska, Silvia Schmidtova, Katarina Kalavska, Jana Obertova, Patrik Palacka, Valentina De Angelis, Peter Lesko, Zuzana Orszaghova, Katarina Rejlekova, Maria Reckova, Zuzana Sycova-Mila, Jozef Mardiak, Michal Chovanec, Lucia Kucerova
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Nikola Hapakova, Michal Chovanec, Katarina Rejlekova, Katarina Kalavska, Jana Obertova, Patrik Palacka, Valentina De Angelis, Zuzana Sycova-Mila, Jozef Mardiak, Michal Mego
Summary: This study evaluated the effect of low-molecular-weight heparin prophylaxis on the incidence of VTE in patients with testicular germ cell tumors receiving chemotherapy. It found that prophylactic treatment did not significantly decrease the occurrence of VTE, and patients with extragonadal tumors had a higher incidence of treatment-related deaths.
Article
Urology & Nephrology
Michal Mego, Katarina Rejlekova, Daniela Svetlovska, Vera Miskovska, Ad J. M. Gillis, Valentina De Angelis, Katarina Kalavska, Jana Obertova, Patrik Palacka, Maria Reckova, Zuzana Sycova-Mila, Daniel Pindak, Michal Chovanec, Leendert H. J. Looijenga, Jozef Mardiak
Summary: This study investigated the efficacy and safety of TIP regimen in germ cell tumor patients with an unfavorable decline of STMs after the first cycle of chemotherapy. Although some patients achieved complete response, the overall findings did not support the replacement of BEP regimen with TIP as the standard treatment option for this patient population. TIP was well tolerated, but did not improve outcomes significantly.
EUROPEAN UROLOGY OPEN SCIENCE
(2021)
